Evidence map›Paper›PMID 42434703›Full record

ArticleChina CDC weekly2026

Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023.

Hanlu Jia, Yan Zhao, Yuan Guan, Jiang Liu, Yunxia Geng, Xiumin Gan, Yufen Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanlu JiaNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yan ZhaoNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuan GuanNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jiang LiuNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yunxia GengNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiumin GanNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yufen LiuNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: Antiretroviral therapy (ART) is the cornerstone of HIV care. In China, efavirenz-based regimens have long been widely used as first-line treatment, while integrase strand transfer inhibitor (INSTI)-based regimens are increasingly available. However, nationwide evidence on virologic outcomes across common first-line regimens remains limited. What is added by this report?: This nationwide cohort study found higher viral suppression with EFV 400 mg-based regimens compared with EFV 600 mg- and LPV/r-based regimens, while INSTI-based regimens showed the highest suppression overall. What are the implications for public health practice?: Findings support expanded use of INSTI-based regimens and consideration of EFV 400 mg-based regimens during ongoing optimization of first-line ART in China.

Indexed as

Antiretroviral therapyHuman immunodeficiency virusViral suppression

Identifiers

PMID42434703
PMCPMC13351181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.